Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has led to more than 150 million infections and about 3.1 million deaths up to date. Currently, drugs screened are urgently aiming to block the infection of SARS-CoV-2. Here, we explored the interaction networks of kinase and COVID-19 crosstalk, and identified phosphoinositide 3-kinase (PI3K)/AKT pathway as the most important kinase signal pathway involving COVID-19. Further, we found a PI3K/AKT signal pathway inhibitor capivasertib restricted the entry of SARS-CoV-2 into cells under non-cytotoxic concentrations. Lastly, the signal axis PI3K/AKT/FYVE finger-containing phosphoinositide kinase (PIKfyve)/PtdIns(3,5)P2 was revealed to play a key role during the cellular entry of viruses including SARS-CoV-2, possibly providing potential antiviral targets. Altogether, our study suggests that the PI3K/AKT kinase inhibitor drugs may be a promising anti-SARS-CoV-2 strategy for clinical application, especially for managing cancer patients with COVID-19 in the pandemic era.
【저자키워드】 COVID-19, SARS-CoV-2, antiviral activity, AKT inhibitor, capivasertib, 【초록키워드】 Coronavirus disease 2019, coronavirus, Antiviral, Infection, drug, virus, anti-SARS-CoV-2, death, pathway, pandemic era, targets, cellular entry, inhibitor, Interaction, cancer patient, acute respiratory syndrome, Cell, concentrations, caused, screened, entry of SARS-CoV-2, with COVID-19, 【제목키워드】 cellular, restrict,